Biogen’s Jolly Good Showing

Of course, one can’t have everything, and the quarterly figures did reveal a slight dip in revenue – a mere 7%, and hardly a catastrophe. Net income, following the usual accounting rigmarole, also took a bit of a tumble, falling to just under $294 million. But here’s the thing, you see: the chaps who make these sorts of predictions – the analysts, you understand – were expecting something considerably less. They were anticipating a revenue of $2.21 billion, and a paltry $1.61 per share for non-GAAP net income. Biogen, however, breezed past those numbers with the nonchalance of a seasoned golfer.






